Dr Reddy's launches anti-epilepsy tablets in US market

NEW DELHI: Drug firm Dr Reddy's Laboratories today said it has launched its generic Lamotrigine extended-release tablets, used for treating epilepsy, in the American market following approval by the US health regulator.


The company has launched Lamotrigine extended-release tablets in the US market on June 25, 2013, after its abbreviated new drug application (ANDA) was approved by the United States Food and Drug Administration (USFDA), Dr Reddy's said in a filing with BSE.

The approval is for the product in the strengths of 25 mg, 50 mg, 100 mg, 200 mg and 300 mg, it added.

The company's product is generic version of GlaxoSmithKline's Lamictal XR tablets, it said.

"Lamictal XR brand and generic had combined US sales of approximately USD 300.5 million for the most recent twelve months ending April 2013, according to IMS Health," the statement added.

Shares of Dr Reddy's Laboratories were today trading at Rs 2,093.15 on BSE, down 0.32 per cent from its previous close.